zifeng-ai/TrialReviewBench huggingface dataset:
Clinical trial (2014, phase 3) in Melanoma
Treatment arms: nivolumab 3 mg/kg every 2 weeks vs. dacarbazine 1 g/m2 every 3 weeks
Patients per arm: 206 vs. 205
Nephritis, grade 1-5: not available vs. not available
Nephritis, grade 3-5: not available vs. not available
Blood creatinine increased, grade 1-5: 1 vs. 1
Blood creatinine increased, grade 3-5: 0 vs. 0
Acute kidney injury, grade 1-5: 1 vs. 0
Acute kidney injury, grade 3-5: 1 vs. 0
Clinical trial (2015, phase 2) in Melanoma
Treatment arms: pembrolizumab 2 mg/kg every 3 weeks vs. pembrolizumab 10 mg/kg every 3 weeks vs. investigator’s choice of chemotherapy every 3 weeks
Patients per arm: 178 vs. 179 vs. 171
Nephritis, grade 1-5: 1 vs. 1 vs. 0
Nephritis, grade 3-5: 0 vs. 0 vs. 0
Blood creatinine increased, grade 1-5: not available vs. not available vs. not available
Blood creatinine increased, grade 3-5: not available vs. not available vs. not available
Acute kidney injury, grade 1-5: not available vs. not available vs. not available
Acute kidney injury, grade 3-5: not available vs. not available vs. not available
Clinical trial (2015, phase 3) in Melanoma
Treatment arms: pembrolizumab 10 mg/kg every 2/3 weeks vs. Ipilimumab 3 mg/kg every 3 weeks
Patients per arm: 555 vs. 256
Nephritis, grade 1-5: 1 vs. 1
Nephritis, grade 3-5: 0 vs. 1
Blood creatinine increased, grade 1-5: not available vs. not available
Blood creatinine increased, grade 3-5: not available vs. not available
Acute kidney injury, grade 1-5: not available vs. not available
Acute kidney injury, grade 3-5: not available vs. not available
Clinical trial (2015, phase 3) in NSCL
Treatment arms: nivolumab 3 mg/kg every 2 weeks vs. docetaxel 75 mg/m2 every 3 weeks
Patients per arm: 287 vs. 268
Nephritis, grade 1-5: not available vs. not available
Nephritis, grade 3-5: not available vs. not available
Blood creatinine increased, grade 1-5: 5 vs. 1
Blood creatinine increased, grade 3-5: 0 vs. 0
Acute kidney injury, grade 1-5: 1 vs. 0
Acute kidney injury, grade 3-5: 0 vs. 0
Clinical trial (2015, phase 3) in Melanoma
Treatment arms: nivolumab 3 mg/kg every 2 weeks vs. investigator’s choice of chemotherapy every 3 weeks
Patients per arm: 268 vs. 102
Nephritis, grade 1-5: not available vs. not available
Nephritis, grade 3-5: not available vs. not available
Blood creatinine increased, grade 1-5: 2 vs. 0
Blood creatinine increased, grade 3-5: 0 vs. 0
Acute kidney injury, grade 1-5: not available vs. not available
Acute kidney injury, grade 3-5: not available vs. not available
Clinical trial (2016, phase 3) in NSCL
Treatment arms: pembrolizumab 200 mg every 3 weeks vs. platinum-based chemotherapy
Patients per arm: 154 vs. 150
Nephritis, grade 1-5: 1 vs. 0
Nephritis, grade 3-5: 1 vs. 0
Blood creatinine increased, grade 1-5: 3 vs. 15
Blood creatinine increased, grade 3-5: 0 vs. 1
Acute kidney injury, grade 1-5: not available vs. not available
Acute kidney injury, grade 3-5: not available vs. not available
Clinical trial (2016, phase 3) in Head-and-neck
Treatment arms: nivolumab 3 mg/kg every 2 weeks vs. Methotrexate/docetaxel/cetuximab
Patients per arm: 236 vs. 111
Nephritis, grade 1-5: not available vs. not available
Nephritis, grade 3-5: not available vs. not available
Blood creatinine increased, grade 1-5: not available vs. not available
Blood creatinine increased, grade 3-5: not available vs. not available
Acute kidney injury, grade 1-5: 1 vs. 2
Acute kidney injury, grade 3-5: 0 vs. 1
Clinical trial (2016, phase 2/3) in NSCL
Treatment arms: pembrolizumab 2 mg/kg every 3 weeks vs. pembrolizumab 10 mg/kg every 3 weeks vs. docetaxel 75 mg/m2 every 3 weeks
Patients per arm: 339 vs. 343 vs. 309
Nephritis, grade 1-5: not available vs. not available vs. not available
Nephritis, grade 3-5: not available vs. not available vs. not available
Blood creatinine increased, grade 1-5: 6 vs. 7 vs. 0
Blood creatinine increased, grade 3-5: 0 vs. 0 vs. 0
Acute kidney injury, grade 1-5: not available vs. not available vs. not available
Acute kidney injury, grade 3-5: not available vs. not available vs. not available
Clinical trial (2017, phase 3) in Urothelial Carcinoma
Treatment arms: pembrolizumab 200 mg every 3 weeks vs. investigator’s choice of chemotherapy every 3 weeks
Patients per arm: 266 vs. 255
Nephritis, grade 1-5: 2 vs. 0
Nephritis, grade 3-5: 2 vs. 0
Blood creatinine increased, grade 1-5: 13 vs. 15
Blood creatinine increased, grade 3-5: 2 vs. 1
Acute kidney injury, grade 1-5: 15 vs. 7
Acute kidney injury, grade 3-5: 7 vs. 3
Clinical trial (2017, phase 3) in NSCL
Treatment arms: nivolumab 3 mg/kg every 2 weeks vs. Platinum-based investigator’s choice of chemotherapy every 3 weeks
Patients per arm: 267 vs. 263
Nephritis, grade 1-5: not available vs. not available
Nephritis, grade 3-5: not available vs. not available
Blood creatinine increased, grade 1-5: 5 vs. 16
Blood creatinine increased, grade 3-5: 1 vs. 0
Acute kidney injury, grade 1-5: not available vs. not available
Acute kidney injury, grade 3-5: not available vs. not available
Clinical trial (2017, phase 3) in SC-NSCL
Treatment arms: nivolumab 3 mg/kg every 2 weeks vs. Docetaxel 75 mg/m2 every 3 weeks
Patients per arm: 131 vs. 129
Nephritis, grade 1-5: 1 vs. 0
Nephritis, grade 3-5: 1 vs. 0
Blood creatinine increased, grade 1-5: 4 vs. 2
Blood creatinine increased, grade 3-5: 0 vs. 0
Acute kidney injury, grade 1-5: 0 vs. 1
Acute kidney injury, grade 3-5: 0 vs. 1
Clinical trial (2017, phase 3) in Melanoma
Treatment arms: Pembrolizumab 10 mg/kg every 3 weeks vs. ipilimumab 3 mg/kg every 3 weeks
Patients per arm: 277 vs. 278
Nephritis, grade 1-5: 2 vs. 0
Nephritis, grade 3-5: 2 vs. 0
Blood creatinine increased, grade 1-5: not available vs. not available
Blood creatinine increased, grade 3-5: not available vs. not available
Acute kidney injury, grade 1-5: not available vs. not available
Acute kidney injury, grade 3-5: not available vs. not available
Clinical trial (2018, phase 3) in Head-and-neck
Treatment arms: pembrolizumab 200 mg every 3 weeks vs. Methotrexate/docetaxel
Patients per arm: 246 vs. 234
Nephritis, grade 1-5: not available vs. not available
Nephritis, grade 3-5: not available vs. not available
Blood creatinine increased, grade 1-5: 0 vs. 2
Blood creatinine increased, grade 3-5: 0 vs. 0
Acute kidney injury, grade 1-5: 1 vs. 1
Acute kidney injury, grade 3-5: 1 vs. 0
Clinical trial (2018, phase 3) in NSCL
Treatment arms: Avelumab 10 mg/kg every 2 weeks vs. Docetaxel 75 mg/m2 every 3 weeks
Patients per arm: 393 vs. 365
Nephritis, grade 1-5: not available vs. not available
Nephritis, grade 3-5: not available vs. not available
Blood creatinine increased, grade 1-5: not available vs. not available
Blood creatinine increased, grade 3-5: not available vs. not available
Acute kidney injury, grade 1-5: 1 vs. 0
Acute kidney injury, grade 3-5: 1 vs. 0
Clinical trial (2018, phase 3) in Melanoma
Treatment arms: Pembrolizumab 200 mg every 3 weeks vs. placebo every 3 weeks
Patients per arm: 509 vs. 502
Nephritis, grade 1-5: 2 vs. 1
Nephritis, grade 3-5: 2 vs. 0
Blood creatinine increased, grade 1-5: not available vs. not available
Blood creatinine increased, grade 3-5: not available vs. not available
Acute kidney injury, grade 1-5: not available vs. not available
Acute kidney injury, grade 3-5: not available vs. not available
Clinical trial (2018, phase 3) in NSCL
Treatment arms: Atezolizumab vs. Docetaxel
Patients per arm: 56 vs. 45
Nephritis, grade 1-5: 1 vs. 0
Nephritis, grade 3-5: 1 vs. 0
Blood creatinine increased, grade 1-5: not available vs. not available
Blood creatinine increased, grade 3-5: not available vs. not available
Acute kidney injury, grade 1-5: not available vs. not available
Acute kidney injury, grade 3-5: not available vs. not available
Clinical trial (2019, phase 3) in NSCL
Treatment arms: pembrolizumab 200 mg every 3 weeks vs. Platinum-based investigator’s choice of chemotherapy every 3 weeks
Patients per arm: 636 vs. 615
Nephritis, grade 1-5: 3 vs. 0
Nephritis, grade 3-5: 1 vs. 0
Blood creatinine increased, grade 1-5: not available vs. not available
Blood creatinine increased, grade 3-5: not available vs. not available
Acute kidney injury, grade 1-5: not available vs. not available
Acute kidney injury, grade 3-5: not available vs. not available
Clinical trial (2019, phase 3) in Renal cell carcinoma
Treatment arms: nivolumab 3 mg/kg every 3 weeks vs. Everolimus 10 mg every day
Patients per arm: 37 vs. 26
Nephritis, grade 1-5: not available vs. not available
Nephritis, grade 3-5: not available vs. not available
Blood creatinine increased, grade 1-5: 1 vs. 4
Blood creatinine increased, grade 3-5: 0 vs. 0
Acute kidney injury, grade 1-5: not available vs. not available
Acute kidney injury, grade 3-5: not available vs. not available
Clinical trial (2016, phase 3) in Advanced melanoma
Treatment arms: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg, Ipilimumab 3 mg/kg + placebo
Patients per arm: 150
Nephritis, grade 1-5: not available
Nephritis, grade 3-5: not available
Blood creatinine increased, grade 1-5: 2
Blood creatinine increased, grade 3-5: 1
Acute kidney injury, grade 1-5: not available
Acute kidney injury, grade 3-5: not available
Clinical trial (2017, phase 3) in Advanced melanoma
Treatment arms: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks, Ipilimumab 3 mg/kg + placebo
Patients per arm: 624
Nephritis, grade 1-5: not available
Nephritis, grade 3-5: not available
Blood creatinine increased, grade 1-5: 19
Blood creatinine increased, grade 3-5: 1
Acute kidney injury, grade 1-5: not available
Acute kidney injury, grade 3-5: not available
Clinical trial (2018, phase 3) in Non-squamous non-small cell lung cancer
Treatment arms: Pembrolizumab 200 mg + Platinum-based investigator’s choice of chemotherapy every 3 weeks, Placebo + Platinum-based investigator’s choice of chemotherapy every 3 weeks
Patients per arm: 607
Nephritis, grade 1-5: 7
Nephritis, grade 3-5: 6
Blood creatinine increased, grade 1-5: 47
Blood creatinine increased, grade 3-5: 2
Acute kidney injury, grade 1-5: 22
Acute kidney injury, grade 3-5: 9
Clinical trial (2018, phase 3) in extensive-stage small-cell lung cancer
Treatment arms: Atezolizumab 1200 mg + chemotherapy (Carboplatin + Etoposide) every 3 weeks, Placebo + chemotherapy (Carboplatin + Etoposide) every 3 weeks
Patients per arm: 394
Nephritis, grade 1-5: 2
Nephritis, grade 3-5: 1
Blood creatinine increased, grade 1-5: 1
Blood creatinine increased, grade 3-5: 0
Acute kidney injury, grade 1-5: 5
Acute kidney injury, grade 3-5: 2
Clinical trial (2018, phase 3) in Squamous-cell non-small cell lung cancer
Treatment arms: Pembrolizumab 200 mg + chemotherapy (Carboplatin + [Nab-]paclitaxel) every 3 weeks, Placebo + chemotherapy (Carboplatin + [Nab-]paclitaxel) every 3 weeks
Patients per arm: 558
Nephritis, grade 1-5: 4
Nephritis, grade 3-5: 4
Blood creatinine increased, grade 1-5: not available
Blood creatinine increased, grade 3-5: not available
Acute kidney injury, grade 1-5: 1
Acute kidney injury, grade 3-5: 1
Clinical trial (2018, phase 3) in First-line non-small cell lung cancer
Treatment arms: Atezolizumab 1200 mg + Bevacizumab + Carboplatin + Paclitaxel every 3 weeks, Bevacizumab 15 mg/kg + Carboplatin + Paclitaxel every 3 weeks
Patients per arm: 787
Nephritis, grade 1-5: 3
Nephritis, grade 3-5: 1
Blood creatinine increased, grade 1-5: not available
Blood creatinine increased, grade 3-5: not available
Acute kidney injury, grade 1-5: 3
Acute kidney injury, grade 3-5: 2
Clinical trial (2018, phase 3) in Triple-negative breast cancer
Treatment arms: Atezolizumab 840 mg + Nab-paclitaxel 100 mg/m2 d1,8,15 every 4 weeks, Placebo + Nab-paclitaxel 100 mg/m2 d1,8,15 every 4 weeks
Patients per arm: 890
Nephritis, grade 1-5: 1
Nephritis, grade 3-5: 0
Blood creatinine increased, grade 1-5: not available
Blood creatinine increased, grade 3-5: not available
Acute kidney injury, grade 1-5: not available
Acute kidney injury, grade 3-5: not available
Clinical trial (2016, phase 2) in Non-squamous non-small cell lung cancer
Treatment arms: Pembrolizumab 200 mg + chemotherapy (Carboplatin + pemetrexed) every 3 weeks, chemotherapy (Carboplatin + pemetrexed) every 3 weeks
Patients per arm: 121
Nephritis, grade 1-5: not available
Nephritis, grade 3-5: not available
Blood creatinine increased, grade 1-5: 10
Blood creatinine increased, grade 3-5: 0
Acute kidney injury, grade 1-5: 3
Acute kidney injury, grade 3-5: 2
Clinical trial (2019, phase 3) in Non-squamous non-small cell lung cancer
Treatment arms: Atezolizumab 1200 mg + Carboplatin AUC6 q3w + Nab-paclitaxel 100mg/m2 qw, Carboplatin AUC6 q3w + Nab-paclitaxel 100mg/m2 qw
Patients per arm: 705
Nephritis, grade 1-5: 4
Nephritis, grade 3-5: 1
Blood creatinine increased, grade 1-5: 33
Blood creatinine increased, grade 3-5: 2
Acute kidney injury, grade 1-5: 12
Acute kidney injury, grade 3-5: 5